161 related articles for article (PubMed ID: 38818888)
21. Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.
Pinkerton JV; Simon J; Panay N; Seitz C; Parke S; Caetano C; Mellinger U; Haseli Mashhadi N; Haberland C; Atanackovic G; Holz C; Mao G; Morrison M; Nisius S; Schaefers M; Zuurman L
Menopause; 2024 Jun; 31(6):522-529. PubMed ID: 38564691
[TBL] [Abstract][Full Text] [Related]
22. Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.
Neal-Perry G; Cano A; Lederman S; Nappi RE; Santoro N; Wolfman W; English M; Franklin C; Valluri U; Ottery FD
Obstet Gynecol; 2023 Apr; 141(4):737-747. PubMed ID: 36897180
[TBL] [Abstract][Full Text] [Related]
23. Effects of neurokinin 3 receptor antagonist fezolinetant on hot flash-like symptoms in ovariectomized rats.
Tahara A; Takamatsu H; Ohtake A; Tanaka-Amino K; Kaku S
Eur J Pharmacol; 2021 Aug; 905():174207. PubMed ID: 34048742
[TBL] [Abstract][Full Text] [Related]
24. Clinical investigation of RAD1901, a novel estrogen receptor ligand, for the treatment of postmenopausal vasomotor symptoms: a phase 2 randomized, placebo-controlled, double-blind, dose-ranging, proof-of-concept trial.
Hattersley G; Harris AG; Simon JA; Constantine GD
Menopause; 2017 Jan; 24(1):92-99. PubMed ID: 27575546
[TBL] [Abstract][Full Text] [Related]
25. Fezolinetant: A Potential Treatment for Moderate to Severe Vasomotor Symptoms of Menopause.
DePree B
touchREV Endocrinol; 2023 Nov; 19(2):69-72. PubMed ID: 38187079
[TBL] [Abstract][Full Text] [Related]
26. Estimation of placebo effect in randomized placebo-controlled trials for moderate or severe vasomotor symptoms: a meta-analysis.
Zhou T
Menopause; 2023 Jan; 30(1):5-10. PubMed ID: 36576440
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Continuous Transdermal Nitroglycerin for Treating Hot Flashes by Inducing Nitrate Cross-tolerance in Perimenopausal and Postmenopausal Women: A Randomized Clinical Trial.
Huang AJ; Cummings SR; Ganz P; Schembri M; Raghunathan H; Vittinghoff E; Gibson CJ; Grady D
JAMA Intern Med; 2023 Aug; 183(8):776-783. PubMed ID: 37273224
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
Speroff L; Gass M; Constantine G; Olivier S;
Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
[TBL] [Abstract][Full Text] [Related]
29. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial.
Joffe H; Guthrie KA; LaCroix AZ; Reed SD; Ensrud KE; Manson JE; Newton KM; Freeman EW; Anderson GL; Larson JC; Hunt J; Shifren J; Rexrode KM; Caan B; Sternfeld B; Carpenter JS; Cohen L
JAMA Intern Med; 2014 Jul; 174(7):1058-66. PubMed ID: 24861828
[TBL] [Abstract][Full Text] [Related]
30. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
[TBL] [Abstract][Full Text] [Related]
31. Fezolinetant in the treatment of vasomotor symptoms associated with menopause.
Depypere H; Lademacher C; Siddiqui E; Fraser GL
Expert Opin Investig Drugs; 2021 Jul; 30(7):681-694. PubMed ID: 33724119
[No Abstract] [Full Text] [Related]
32. Fezolinetant: First Approval.
Lee A
Drugs; 2023 Aug; 83(12):1137-1141. PubMed ID: 37462862
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1).
Simon JA; Anderson RA; Ballantyne E; Bolognese J; Caetano C; Joffe H; Kerr M; Panay N; Seitz C; Seymore S; Trower M; Zuurman L; Pawsey S
Menopause; 2023 Mar; 30(3):239-246. PubMed ID: 36720081
[TBL] [Abstract][Full Text] [Related]
34. Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials.
Archer DF; Freeman EW; Komm BS; Ryan KA; Yu CR; Mirkin S; Pinkerton JV
J Womens Health (Larchmt); 2016 Nov; 25(11):1102-1111. PubMed ID: 27676118
[TBL] [Abstract][Full Text] [Related]
35. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.
Pinkerton JV; Constantine G; Hwang E; Cheng RF;
Menopause; 2013 Jan; 20(1):28-37. PubMed ID: 23010882
[TBL] [Abstract][Full Text] [Related]
36. Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia menopause (PAM) study.
Tan D; Haines CJ; Limpaphayom KK; Holinka CF; Ausmanas MK
Maturitas; 2005 Sep; 52(1):35-51. PubMed ID: 16211697
[TBL] [Abstract][Full Text] [Related]
37. Menopausal symptom management: Fezolinetant's varied doses provide effective relief for vasomotor symptoms in women - A meta-analysis of 3291 participants.
Elhusein AM; Fadlalmola HA; Abedelwahed HH; Elshaikh AA; Banaga AE; Alrahman MHF; Abdelgadim NH; Mohammed IH; Abdalla AAA; Abdalla FAM; Abd Allah EM; Abbas NI; Alhujaili AD; Almkiy EA; Idress EA; Awadalkareem EM; Abdeldafie SY; Balusamy P; Mohamed RA; Aloufi RSM; Habiballa M; Abdelmalik MA; Alhejaili MM; Ibrahim IA; Masaad HK
Afr J Reprod Health; 2024 Mar; 28(3):99-113. PubMed ID: 38583073
[TBL] [Abstract][Full Text] [Related]
38. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety.
Archer DF; Dupont CM; Constantine GD; Pickar JH; Olivier S;
Am J Obstet Gynecol; 2009 Mar; 200(3):238.e1-238.e10. PubMed ID: 19167693
[TBL] [Abstract][Full Text] [Related]
39. A 12-week clinical trial determining the efficacy of synthetic conjugated estrogens, A (SCE), in the treatment of vasomotor symptoms in menopausal women.
Stevens RE; Hanford K; Wason S; Cusack SL; Phelps KV
Int J Fertil Womens Med; 2000; 45(4):264-72. PubMed ID: 10997482
[TBL] [Abstract][Full Text] [Related]
40. Oral micronized progesterone for vasomotor symptoms--a placebo-controlled randomized trial in healthy postmenopausal women.
Hitchcock CL; Prior JC
Menopause; 2012 Aug; 19(8):886-93. PubMed ID: 22453200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]